Literature DB >> 10361507

Use of peripheral blood blasts vs bone marrow blasts for diagnosis of acute leukemia.

R Weinkauff1, E H Estey, P Starostik, K Hayes, Y O Huh, C Hirsch-Ginsberg, M Andreeff, M Keating, H M Kantarjian, E J Freireich, M Albitar.   

Abstract

Acute leukemia can be diagnosed when blasts constitute 30% or more of the nucleated cells in a patient's peripheral blood (PB) sample. To determine whether in such cases bone marrow (BM) aspirates are still necessary, we compared the results of diagnostic studies performed on PB samples with blast counts of 30% or more with those performed on the same patients' BM samples. We found no differences in morphologic features, cytochemistry, or immunophenotype between the blasts in PB and BM samples in any of 30 cases studied. However, in 10 (23%) of 44 cases in which cytogenetic analysis was performed, PB but not BM samples were insufficient for analysis. The converse never occurred. Five of the 10 cases had acute lymphoblastic leukemia and 5 had acute myeloid leukemia (41% of the patients with acute lymphoblastic leukemia and 17% of the patients with acute myeloid leukemia). In cases with adequate metaphases, there was strong correlation between the cytogenetic results for PB and BM samples. Some PB samples with blast counts of 30% or more are adequate for diagnosis of acute leukemia, especially when therapy can be delayed until it is known that an adequate number of analyzable metaphases are recovered from the PB samples.

Entities:  

Mesh:

Year:  1999        PMID: 10361507     DOI: 10.1093/ajcp/111.6.733

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  12 in total

Review 1.  Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia.

Authors:  Mary-Elizabeth Percival; Catherine Lai; Elihu Estey; Christopher S Hourigan
Journal:  Blood Rev       Date:  2017-02-02       Impact factor: 8.250

2.  Correlation between peripheral blood and bone marrow regarding FLT3-ITD and NPM1 mutational status in patients with acute myeloid leukemia.

Authors:  Wei-Gang Tong; Vicky K Sandhu; Brent L Wood; Paul C Hendrie; Pamela S Becker; John M Pagel; Roland B Walter; Elihu H Estey
Journal:  Haematologica       Date:  2014-12-19       Impact factor: 9.941

3.  Acute myeloid leukemia therapy and the chosen people.

Authors:  E Estey; R P Gale
Journal:  Leukemia       Date:  2016-11-11       Impact factor: 11.528

4.  New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: cancer and leukemia group B 8461.

Authors:  Alison Walker; Krzysztof Mrózek; Jessica Kohlschmidt; Kathleen W Rao; Mark J Pettenati; Lisa J Sterling; Guido Marcucci; Andrew J Carroll; Clara D Bloomfield
Journal:  Genes Chromosomes Cancer       Date:  2012-12-10       Impact factor: 5.006

5.  Deregulation of miR-1, miR486, and let-7a in cytogenetically normal acute myeloid leukemia: association with NPM1 and FLT3 mutation and clinical characteristics.

Authors:  Samaneh Sadat Seyyedi; Masoud Soleimani; Marjan Yaghmaie; Monireh Ajami; Mansoureh Ajami; Shahram Pourbeyranvand; Kamran Alimoghaddam; Seyed Mohammad Akrami
Journal:  Tumour Biol       Date:  2015-11-02

6.  Immunophenotypic Characteristics of T-Acute Lymphoblastic Leukemia in Omani Patients: A Correlation with Demographic Factors.

Authors:  Azza Al-Mashaikhi; Zahra Al Khatri; Sahima Al Mamari; Murtadha Al Khabori; Anil Pathare; Naglaa Fawaz
Journal:  Oman Med J       Date:  2018-01

7.  Section E6.1-6.4 of the ACMG technical standards and guidelines: chromosome studies of neoplastic blood and bone marrow-acquired chromosomal abnormalities.

Authors:  Fady M Mikhail; Nyla A Heerema; Kathleen W Rao; Rachel D Burnside; Athena M Cherry; Linda D Cooley
Journal:  Genet Med       Date:  2016-04-28       Impact factor: 8.822

8.  Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical Response.

Authors:  Hong Yuen Wong; Anthony D Sung; Katherine E Lindblad; Sheenu Sheela; Gregory W Roloff; David Rizzieri; Meghali Goswami; Matthew P Mulé; Nestor R Ramos; Jingrong Tang; Julie Thompson; Christin B DeStefano; Kristi Romero; Laura W Dillon; Dong-Yun Kim; Catherine Lai; Christopher S Hourigan
Journal:  Front Oncol       Date:  2019-01-15       Impact factor: 6.244

9.  Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing.

Authors:  Vidya Balagopal; Andrew Hantel; Sabah Kadri; George Steinhardt; Chao Jie Zhen; Wenjun Kang; Pankhuri Wanjari; Lauren L Ritterhouse; Wendy Stock; Jeremy P Segal
Journal:  PLoS One       Date:  2019-10-28       Impact factor: 3.240

10.  Repeat to gene expression ratios in leukemic blast cells can stratify risk prediction in acute myeloid leukemia.

Authors:  M Onishi-Seebacher; G Erikson; Z Sawitzki; D Ryan; G Greve; M Lübbert; T Jenuwein
Journal:  BMC Med Genomics       Date:  2021-06-26       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.